Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 17649794)

  • 1. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
    Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
    Miyake Y; Kodama T; Yamaguchi K
    Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
    Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
    Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
    Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
    Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
    Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y
    Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) as serum markers in the diagnosis of bronchial carcinoma].
    Lorenz J; Gillmann-Blum D; Jensen M; Kreienberg R
    Pneumologie; 1990 Nov; 44(11):1259-63. PubMed ID: 2177891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determination of various tumor markers, with special reference to neuron-specific enolase in lung cancer].
    Yano H; Hino M; Nishiwaki Y; Kodama T; Hayashibe A; Kudo H; Inoue Y; Nishiyama Y; Sone Y; Oshima T
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):77-83. PubMed ID: 3026257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
    Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
    Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of a multiple biomarker assay in bronchoalveolar lavage (BAL) and serum for the diagnosis of small cell lung cancer.
    Nikliński J; Chyczewska E; Furman M; Kowal E; Laudanski J; Chyczewski L
    Neoplasma; 1993; 40(5):305-8. PubMed ID: 8272160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple tumour markers for diagnosis, management and follow-up of potentially resectable lung cancer.
    Ratto GB; Mereu C; Rovida S
    Panminerva Med; 1993 Dec; 35(4):186-92. PubMed ID: 8202329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of neuron specific enolase and tissue polipeptidic antigen for the management of patients with lung cancer.
    Spinazzi A; Soresi E; Borghini U; Boffi R; Vigorelli R; Scoccia S
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):141-5. PubMed ID: 1965446
    [No Abstract]   [Full Text] [Related]  

  • 16. [Diagnostic significance of the tumor markers CEA, SCC and NSE in serum and bronchoalveolar lavage].
    von Eiff M; Koch O; Appelhans N; Roos N; van de Loo J
    Pneumologie; 1990 Feb; 44 Suppl 1():462-4. PubMed ID: 2164198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of tumor markers in the management of small cell lung cancer].
    Ariyoshi Y
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer.
    Giovanella L; Ceriani L; Bandera M; Beghe B; Roncari G
    Int J Biol Markers; 1995; 10(3):156-60. PubMed ID: 8551058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum neuron-specific enolase (NSE) in patients with small cell lung cancer--comparison with carcinoembryonic antigen (CEA)].
    Kawahara M; Furuse K; Arai R; Tsuruta M; Kodama N; Hayashi S; Kiyota M; Kubota K; Mori T; Yamamoto S
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):146-51. PubMed ID: 3026253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
    Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.